Abstract:Background: STAT3 (signal transducer and activator of transcription 3) is a member of the STAT family of proteins that function as signal transducers and transcription factors. Previous research has demonstrated its importance in cell proliferation, differentiation, apoptosis, and immunological and inflammatory responses. Targeting the STAT3 protein has recently been hailed as a viable cancer therapeutic method. Even though none of these inhibitors have yet been exploited in clinical cancer therapy, a small number have made them into clinical trials, leading researchers to explore more promising inhibitors. Methods: Based on the mechanism of STAT3 activation, several types of STAT3 inhibitors were described and summarized according to their origins, structures, bioactivity and mechanism of action. Direct inhibition of STAT3 mainly targeted one of the three distinct structural regions of the protein, namely the SH2 domain, the DNA binding domain, and the coiled-coil domain. Results: The progress in STAT3 inhibitor discovery from 2010 to 2021 is comprehensively summarized in this review. STAT3 inhibitors are mainly classified into small molecule inhibitors, natural product inhibitors, and peptides/peptidomimetics. Moreover, it also covers relevant analogues, as well as their core framework. Conclusion: Small-molecule inhibitors of STAT3 like BP-1-102 and BTP analogues displayed great potential against various cancers, while natural products, as well as peptide and peptidomimetics, also showed promising application. Therefore, STAT3 has become a promising target with great research value, and the development of STAT3 inhibitors may provide more therapeutic strategies for STAT3-related diseases.

Novel activators and small-molecule inhibitors of STAT3 in cancer

HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery

Targeting STAT3 in Cancer Immunotherapy

Data from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics

Revisiting Signal Transducer and Activator of Transcription 3 (STAT3) As an Anticancer Target and Its Inhibitor Discovery: Where Are We and Where Should We Go?

STAT3 Pathway in Cancers: Past, Present, and Future.

Discovery of STAT3 Inhibitors: Recent Advances and Future Perspectives

Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation

The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy

Novel inhibitors of the STAT3 signaling pathway: an updated patent review (2014-present)

HJC0152, a Novel STAT3 Inhibitor with Promising Anti-Tumor Effect in Gastric Cancer

STAT3: Key targets of growth-promoting receptor positive breast cancer

A Small Molecule Compound Targeting STAT3 DNA-Binding Domain Inhibits Cancer Cell Proliferation, Migration, and Invasion

Targeting STAT3 Enzyme for Cancer Treatment

The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts

Role of STAT3 signaling pathway in breast cancer

Molecular mechanism, regulation, and therapeutic targeting of the STAT3 signaling pathway in esophageal cancer (Review)

A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells

STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review